ClinicalTrials.gg
CompletedNCT01973387Updated Jul 24, 2018Results posted

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

A Phase 3 interventional study of Rituximab and Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-24.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
18th of 189
160 · median 39
Started
2013
with 6 others
Phase 3
18 of 197
1 open now
Registered
167th of 197
by date

Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 18th largest by enrollment of the 189 interventional ones that give a count, is one of 7 that started in 2013, is one of 18 in phase 3, and was the 167th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Read the detailed description

This is a randomized (individuals assigned to study treatment by chance), open-label (identity of assigned study drug will be known) study designed to evaluate the efficacy and safety of ibrutinib versus rituximab in adult Asia Pacific region patients with relapsed/refractory CLL or SLL with active disease requiring treatment who have failed at least 1 prior line of therapy and are not considered appropriate candidates for treatment or retreatment with purine analog-based therapy. Approximately 150 patients will be randomly assigned in a 1:2 ratio into 2 treatment arms to receive either intravenous rituximab (Treatment Arm A) for 6 cycles or oral ibrutinib (Treatment Arm B) until disease progression or unacceptable toxicity, whichever occurs first. The study will include screening, treatment, and follow-up phases. Treatment will extend from randomization until study drug discontinuation. Follow-up will consist of 2 phases: post-treatment (from the discontinuation of treatment for reasons other than disease progression until the patient has progressive disease) and post-disease progression (subsequent anticancer therapy and survival status will be recorded until death, lost to follow-up, consent withdrawal, or study closure). Patients in the rituximab arm with disease progression or who meet the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria for requiring subsequent anti-CLL therapy may be considered for cross over to receive ibrutinib 420 mg orally, daily until disease progression, unacceptable toxicity, withdrawal from study, or until study end whichever occurs earliest. Efficacy evaluations will assess for disease response and progression in accordance with International Workshop on Chronic Lymphocytic Leukemia 2008 criteria. Serial pharmacokinetic (study of what a drug does to the body) blood samples will be collected in the ibrutinib treatment group. Safety will be assessed throughout the study.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic lymphocytic leukemia
  • Small lymphocytic lymphoma
  • Relapsed or refractory chronic lymphocytic leukemia
  • Relapsed or refractory small lymphocytic lymphoma
  • Ibrutinib
  • PCI-32765
  • Bruton's tyrosine kinase inhibitor
  • Rituximab
  • Asia Pacific region participants
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of 0-1
  • Diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that meets protocol-defined criteria
  • Laboratory values within protocol-defined parameters
  • Active disease meeting International Workshop on Chronic Lymphocytic Leukemia 2008 criteria
  • Received at least 1 prior therapy for CLL/SLL and not appropriate for treatment or retreatment with purine analog-based therapy
  • Measurable nodal disease by computed tomography
  • Female subjects of must have a negative serum or urine pregnancy test at Screening and agree to use highly effective methods of during the study and for 90 days following the last dose with ibrutinib or 12 months following the last dose of rituximab

Exclusion criteria

Exclusion Criteria:

  • Central nervous system lymphoma or leukemia
  • Prolymphocytic leukemia or history of or currently suspected Richter's transformation
  • to prior rituximab-based therapy
  • Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or drug within 30 days prior to first dose of study drug
  • use >20 mg within 1 week prior to first dose of study drug
  • Radio- or toxin-conjugated antibody therapy within 10 weeks prior to first dose of study drug
  • Prior transplant within 6 months prior to first dose of study drug
  • Prior allogeneic stem cell transplant
  • Major surgery within 4 weeks prior to first dose of study drug
  • History of prior according to protocol-defined criteria
  • Currently active cardiovascular disease within 6 months prior to first dose with study drug
  • Uncontrolled active systemic fungal, bacterial, viral, or other ongoing anti-infective treatment administered intravenously
  • History of or active infection with or C
  • History of stroke or intracranial hemorrhage within 6 months prior to random assignment
  • Pregnant or lactating women
  • Current life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, or put the study at risk
  • Requires or receiving anticoagulation with warfarin or equivalent Vitamin K antagonists
  • Requires treatment with a strong /5 inhibitor
  • Uncontrolled hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP), defined as declining or count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (greater than [>]20 milligram [mg] daily of prednisone daily or equivalent)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Treatment Arm A

    Drug: Rituximab

  • Experimental
    Treatment Arm B

    Drug: Ibrutinib

Interventions

  • Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).

  • 420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for progressive disease (PD): New enlarged nodes greater than (\>)1.5 centimeter (cm), new hepatomegaly or splenomegaly, or other organ infiltrates; greater than or equal to (\>=)50 percent (%) increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; New cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to chronic lymphocytic leukemia (CLL) and transformation to a more aggressive histology.

    Time frame: From the date of randomization to the date of disease progression or death, whichever was first reported (Up to 3.7 years)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- \>=50% drop in lymphocyte count from baseline or \<=4.0\*10\^9/L with following: \>=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, \>=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils \>1.5\*10\^9/L, Platelets\>100000/mcL and Hgb\>11 g/dL or \>=50% improvement over baseline in all.

    Time frame: From the date of randomization to disease progression (Up to 3.7 years)

  2. Overall Survival (OS)

    Overall survival was defined as the interval between the date of randomization and the date of death from any cause.

    Time frame: From the date of randomization to the date of death (Up to 3.7 years)

  3. Number of Participants With Sustained Hematologic Improvement

    Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.

    Time frame: From the date of randomization to disease progression (Up to 3.7 years)

  4. Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

    The most common disease-related symptoms associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (fatigue, weight loss, fevers, night sweats, and abdominal discomfort/splenomegaly) were reported by grade.

    Time frame: From the date of randomization to disease progression (Up to 3.7 years)

07

Results

Posted Feb 23, 2017

Participant flow

A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) versus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Participant flow — Overall Study
MilestoneIbrutinibRituximab
Started10654
Treated10452
Completed036
Not completed10618
Withdrew: Adverse event144
Withdrew: Withdrawal by subject74
Withdrew: Study terminated by sponsor630
Withdrew: Progressive disease or relapse165
Withdrew: Death43
Withdrew: Randomized, not treated22

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival was defined as the interval between the date of randomization and the date of disease progression or death, whichever was first reported. International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for progressive disease (PD): New enlarged nodes greater than (\>)1.5 centimeter (cm), new hepatomegaly or splenomegaly, or other organ infiltrates; greater than or equal to (\>=)50 percent (%) increase from nadir in existing lymph node or \>=50% increase from nadir in sum of product of diameters of multiple nodes; \>=50% increase from nadir in enlargement of liver or spleen; \>=50% increase from baseline in lymphocyte count (and to \>=5\*10\^9/L) unless considered treatment-related lymphocytosis; New cytopenia (Hemoglobin b \[Hgb\] or platelets) attributable to chronic lymphocytic leukemia (CLL) and transformation to a more aggressive histology.

Time frame:
From the date of randomization to the date of disease progression or death, whichever was first reported (Up to 3.7 years)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsIbrutinibRituximab
Progression-free Survival (PFS)NA (NA to NA)8.38 (8.31 to 9.03)
Statistical analysis
  • Ibrutinib vs Rituximab · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.178 · 95% CI 0.109 to 0.291
SecondaryOverall Response Rate (ORR)

ORR defined as number of participants achieving a complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR) or partial response (PR). IWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \>1.5\*10\^9/liter (L), platelets \>100\*10\^9/L, Hgb \>11 gram per deciliter (g/dL) and absolute lymphocyte count \<4000/microliter (mcL); CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but the bone marrow biopsy shows B-lymphoid nodules, may represent a clonal infiltrate; PR- \>=50% drop in lymphocyte count from baseline or \<=4.0\*10\^9/L with following: \>=50% decrease in sum products of up to 6 lymph nodes, no new enlarged lymph nodes, When abnormal, \>=50% decrease in enlargement of spleen from baseline or normalization and a response in 1 of following: Neutrophils \>1.5\*10\^9/L, Platelets\>100000/mcL and Hgb\>11 g/dL or \>=50% improvement over baseline in all.

Time frame:
From the date of randomization to disease progression (Up to 3.7 years)
Reported as:
Number · participants
Overall Response Rate (ORR)
participantsIbrutinibRituximab
Overall Response Rate (ORR)664
SecondaryOverall Survival (OS)

Overall survival was defined as the interval between the date of randomization and the date of death from any cause.

Time frame:
From the date of randomization to the date of death (Up to 3.7 years)
Reported as:
Median · months
Overall Survival (OS)
monthsIbrutinibRituximab
Overall Survival (OS)NA (NA to NA)NA (19.52 to NA)
SecondaryNumber of Participants With Sustained Hematologic Improvement

Sustained hematologic improvement was defined as hematological improvement that was sustained continuously for greater than or equal to (\>=) 56 days without blood transfusion or growth factors: 1) Platelet counts greater than (\>)100\* 109/liter (L) if baseline less than or equal to (\<=) 100\*109/L or increase \>= 50 percent (%) over baseline; 2) Hemoglobin \>11 gram per deciliters (g/dL) if baseline \<= 11 g/dL or increase \>= 2 g/dL over baseline.

Time frame:
From the date of randomization to disease progression (Up to 3.7 years)
Reported as:
Number · participants
Number of Participants With Sustained Hematologic Improvement
participantsIbrutinibRituximab
Hemoglobin4314
Platelets4812
SecondaryNumber of Participants With Clinically Relevant Shifts in Disease-Related Symptoms

The most common disease-related symptoms associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (fatigue, weight loss, fevers, night sweats, and abdominal discomfort/splenomegaly) were reported by grade.

Time frame:
From the date of randomization to disease progression (Up to 3.7 years)
Reported as:
Number · participants
Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms
participantsIbrutinibRituximab
Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms00

Adverse events

Collected over Screening up to follow up phase (approximately 3.7 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib21/104 (20.2%)56/104 (53.8%)103/104 (99%)
Rituximab20/52 (38.5%)17/52 (32.7%)46/52 (88.5%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventIbrutinibRituximab
Lung InfectionInfections and infestations12/1046/52
PyrexiaGeneral disorders3/1043/52
PneumoniaInfections and infestations5/1041/52
InfectionInfections and infestations0/1042/52
LymphadenitisBlood and lymphatic system disorders3/1040/52
Atrial FibrillationCardiac disorders3/1040/52
Cardiac FailureCardiac disorders3/1041/52
DeathGeneral disorders3/1040/52
Urinary Tract InfectionInfections and infestations3/1040/52
Respiratory FailureRespiratory, thoracic and mediastinal disorders3/1041/52
Most frequent other events
Showing 10 of 51
Most frequent other events
EventIbrutinibRituximab
DiarrhoeaGastrointestinal disorders41/1044/52
Neutrophil Count DecreasedInvestigations36/10420/52
Platelet Count DecreasedInvestigations33/10414/52
CoughRespiratory, thoracic and mediastinal disorders33/1044/52
RashSkin and subcutaneous tissue disorders31/1043/52
FatigueGeneral disorders30/1046/52
Upper Respiratory Tract InfectionInfections and infestations29/1047/52
PyrexiaGeneral disorders27/10414/52
NeutropeniaBlood and lymphatic system disorders26/10411/52
AnaemiaBlood and lymphatic system disorders20/1045/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)IbrutinibRituximabTotal
Mean63.6 ± 10.3663.6 ± 13.0463.6 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)IbrutinibRituximabTotal
Female291847
Male7736113
Region of Enrollment
Region of Enrollment(Participants)IbrutinibRituximabTotal
Australia15924
China8744131
Malaysia112
Taiwan, Province Of China303
08

Study locations

26 sites
  • Concord, Australia
  • Gosford, Australia
  • Heidelberg, Australia
  • Perth, Australia
  • Tweed Heads, Australia
  • Beijing, China
  • Chendu, China
  • Fuzhou, China
  • Guangzhou, China
  • Jinan, China
  • Nanjing, China
  • Qingdao, China
  • Shanghai, China
  • Suzhou, China
  • Tianjin, China
  • Unk Hangzhou, China
  • Wuhan, China
  • Xian, China
  • Johor Bahru, Malaysia
  • Kuala Lumpur, Malaysia
  • Melaka, Malaysia
  • Subang Jaya, Malaysia
  • Changhua, Taiwan
  • Kaohsiung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Dec 2015, 25 months.

Results were first posted in Feb 2017, 1 year 2 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 25 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2013
First posted
Oct 31, 2013
StartActual
Oct 28, 2013
Primary completionActual
Dec 1, 2015
CompletionActual
Aug 11, 2017
Results first posted
Feb 23, 2017
Last update
Jul 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01973387
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 31, 2013
Start date
Oct 28, 2013
Primary completion
Dec 1, 2015
Completion
Aug 11, 2017
Results posted
Feb 23, 2017
Last update
Jul 24, 2018

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Ibrutinib

Start the discussion